Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (457)	4/5/2006 6:22:00 PM
From: nigel bates	Respond to of 671

>>wish I knew the truth<< Look at how long the IP struggles lasted for monoclonals: stick around for a decade or so... :-) :-(

To: A.J. Mullen who wrote (457)	4/5/2006 6:22:51 PM
From: tuck	Read Replies (2) \| Respond to of 671

This is a patent for a target via this technology, not the technology platform. And who knows if it will hold. The IP situation in this space remains murky, and will be so for some years, despite press releases seeming to claim otherwise. This was discussed in the early days of the thread, before I threw my hands up because I knew there was no way I'd figure it out. There are precious few IP attorneys in the biotech area, and none of them post here on SI, darn it. Cheers, Tuck